Recent research progress on the relation of B-ALL associated cytogenetic and molecular genetic abnormalities with B-ALL prognosis.
10.7534/j.issn.1009-2137.2014.05.057
- Author:
Mei-Rong WU
1
;
Qi WEN
1
;
Cong HUANG
1
;
Yan WANG
1
;
Wen-Fa HUANG
1
;
Ying-Zhi HE
2
;
Yu-Hua LI
3
Author Information
1. Second Clinical Medical College of Southern Medical University, Guangzhou 510282, Guangdong Province, China.
2. Department of Hematology, Southern Medical University Zhujiang Hospital, Guangzhou 510282, Guangdong Province, China.
3. Department of Hematology, Southern Medical University Zhujiang Hospital, Guangzhou 510282, Guangdong Province, China. E-mail: li_yuhua@yahoo.com.
- Publication Type:Journal Article
- MeSH:
Cytogenetic Analysis;
Humans;
Karyotyping;
Neoplasm, Residual;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
diagnosis;
genetics;
Prognosis
- From:
Journal of Experimental Hematology
2014;22(5):1480-1484
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, standardized treatment based on the risk stratification has been applied to clinical diagnosis and treatment of leukemia, which significantly improves the remission rate of ALL. However, relapse after remission remains an important challenge for long term efficacy. Chromosomal karyotype analysis is often used clinically to study the genetic features of ALL. As leukemia-specific markers, the cytogenetic and molecular genetic abnormalities can be used to evaluate prognosis and make an effective and optimal therapy. Furthermore, they are also used to track minimal residual disease. Therefore, the cytogenetic and molecular genetic abnormalities may become a monitor and a new target for the treatment of leukemia. This review briefly introduces the structure and physiological function of B-ALL associated cytogenetic and molecular genetic abnormalities, focusing on their prognostic effect on B-ALL.
